Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C3H3NO |
| Molecular Weight | 69.062 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O1C=CC=N1
InChI
InChIKey=CTAPFRYPJLPFDF-UHFFFAOYSA-N
InChI=1S/C3H3NO/c1-2-4-5-3-1/h1-3H
| Molecular Formula | C3H3NO |
| Molecular Weight | 69.062 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Fluorinated acyclo-C-nucleoside analogues from glycals in two steps. | 2006-07-24 |
|
| Synthesis of enantiopure Delta2-isoxazoline derivatives and evaluation of their affinity and efficacy profiles at human beta-adrenergic receptor subtypes. | 2006-07-01 |
|
| Copper complexes with heterocyclic sulfonamides: synthesis, spectroscopic characterization, microbiological and SOD-like activities: crystal structure of [Cu(sulfisoxazole)2(H2O)4] . 2H2O. | 2006-07 |
|
| Synthesis of pyrazoles and isoxazoles as potent alpha(v)beta3 receptor antagonists. | 2006-06-15 |
|
| Isoxazole-type derivatives related to combretastatin A-4, synthesis and biological evaluation. | 2006-06-15 |
|
| Protective effects of leflunomide against ischemia-reperfusion injury of the rat liver. | 2006-05 |
|
| Practical asymmetric synthesis of a gamma-secretase inhibitor exploiting substrate-controlled intramolecular nitrile oxide-olefin cycloaddition. | 2006-04-14 |
|
| Synthetic heteroprostanoids of A- and E-types as novel non-comprehensive inhibitors of adenylyl cyclase in rat hepatocytes. | 2006-03-10 |
|
| Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib. | 2006-01-15 |
|
| [Antimicrobial therapy in dermatology]. | 2006-01 |
|
| Cyclohexyl-linked tricyclic isoxazoles are potent and selective modulators of the multidrug resistance protein (MRP1). | 2005-12-15 |
|
| The design, synthesis and screening of a muscarinic acetylcholine receptor targeted compound library. | 2005-11 |
|
| New approach to the practical synthesis of tri- or tetrasubstituted pyrimidine derivatives: a four-component coupling reaction from a functionalized silane, two types of aromatic nitriles, and acetals. | 2005-10-13 |
|
| Design of wide-spectrum inhibitors targeting coronavirus main proteases. | 2005-10 |
|
| One-pot construction of pyrazoles and isoxazoles with palladium-catalyzed four-component coupling. | 2005-09-29 |
|
| Antibacterial 4-amino-N-(5-methylisoxazol-3-yl)-N-[(4-oxo-2-phenyl-4H-1-benzopyran-6-yl)methyl]benzenesulfonamide. | 2005-09 |
|
| Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation. | 2005-09 |
|
| Development of a novel and automated fluorescent immunoassay for the analysis of beta-lactam antibiotics. | 2005-08-24 |
|
| Evaluation of the true precocious puberty rats induced by neonatal administration of Danazol: therapeutic effects of nourishing "Yin"-Removing "Fire" Chinese herb mixture. | 2005-08-22 |
|
| Two novel series of allocolchicinoids with modified seven membered B-rings: design, synthesis, inhibition of tubulin assembly and cytotoxicity. | 2005-05-16 |
|
| Theoretical study on the excited states of HCN. | 2005-05-08 |
|
| Dipeptidyl peptidase IV inhibitors derived from beta-aminoacylpiperidines bearing a fused thiazole, oxazole, isoxazole, or pyrazole. | 2005-05-02 |
|
| Tandem mass spectrometric assay of succinylacetone in urine for the diagnosis of hepatorenal tyrosinemia. | 2005-04-15 |
|
| Effect of a Y265F mutant on the transamination-based cycloserine inactivation of alanine racemase. | 2005-04-12 |
|
| Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. | 2005-04-01 |
|
| Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. | 2005-04 |
|
| Staphylococcus aureus bacteremia, Australia. | 2005-04 |
|
| [New findings on the structure-phototoxicity relationship and photostability of fluoroquinolones]. | 2005-03 |
|
| Synthesis of argentatin A derivatives as growth inhibitors of human cancer cell lines in vitro. | 2005-02-15 |
|
| Heterocyclic and phenyl double-bond-locked combretastatin analogues possessing potent apoptosis-inducing activity in HL60 and in MDR cell lines. | 2005-02-10 |
|
| The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function. | 2005 |
|
| Isoxazole ionotropic glutamate neurotransmitters. | 2005 |
|
| Structure and immunological activity of disubstituted thiosemicarbazide isoxazole derivative. | 2004-12 |
|
| New synthetic equivalent of nitromalonaldehyde treatable in organic media. | 2004-11-26 |
|
| Novel isoxazole carboxamides as growth hormone secretagogue receptor (GHS-R) antagonists. | 2004-10-18 |
|
| Surveillance of antimicrobial resistance at a tertiary hospital in Tanzania. | 2004-10-11 |
|
| Suppressive effect of leflunomide metabolite (A77 1726) on metalloproteinase production in IL-1beta stimulated rheumatoid synovial fibroblasts. | 2004-09 |
|
| Synthesis, theoretical and structural analyses, and enantiopharmacology of 3-carboxy homologs of AMPA. | 2004-08 |
|
| 3D QSAR studies on T-type calcium channel blockers using CoMFA and CoMSIA. | 2004-04-01 |
|
| Prevalence of antimicrobial resistance in bacteria isolated from central nervous system specimens as reported by U.S. hospital laboratories from 2000 to 2002. | 2004-03-25 |
|
| Evaluation of the binding of the tricyclic isoxazole photoaffinity label LY475776 to multidrug resistance associated protein 1 (MRP1) orthologs and several ATP- binding cassette (ABC) drug transporters. | 2004-03-15 |
|
| Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. | 2004-03-11 |
|
| Solid-phase synthesis of 5-isoxazol-4-yl-[1,2,4]oxadiazoles. | 2004-03-05 |
|
| Collision-induced dissociation of valdecoxib metabolites: a novel rearrangement involving an isoxazole ring. | 2004-03 |
|
| Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains. | 2004-02-23 |
|
| Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells. | 2004-02-15 |
|
| Synthesis and COX-2 inhibitory properties of N-phenyl- and N-benzyl-substituted amides of 2-(4-methylsulfonylphenyl)cyclopent-1-ene-1-carboxylic acid and of their pyrazole, thiophene and isoxazole analogs. | 2004-01 |
|
| Degradation of isoxaflutole (balance) herbicide by hypochlorite in tap water. | 2003-12-31 |
|
| Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation. | 2003-12-12 |
|
| Non-peptidic small-molecule antagonists of the human platelet thrombin receptor PAR-1. | 2003-03 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:02:29 GMT 2025
by
admin
on
Mon Mar 31 20:02:29 GMT 2025
|
| Record UNII |
00SRW0M6PW
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
ISOXAZOLE
Created by
admin on Mon Mar 31 20:02:29 GMT 2025 , Edited by admin on Mon Mar 31 20:02:29 GMT 2025
|
PRIMARY | |||
|
00SRW0M6PW
Created by
admin on Mon Mar 31 20:02:29 GMT 2025 , Edited by admin on Mon Mar 31 20:02:29 GMT 2025
|
PRIMARY | |||
|
35595
Created by
admin on Mon Mar 31 20:02:29 GMT 2025 , Edited by admin on Mon Mar 31 20:02:29 GMT 2025
|
PRIMARY | |||
|
206-018-7
Created by
admin on Mon Mar 31 20:02:29 GMT 2025 , Edited by admin on Mon Mar 31 20:02:29 GMT 2025
|
PRIMARY | |||
|
288-14-2
Created by
admin on Mon Mar 31 20:02:29 GMT 2025 , Edited by admin on Mon Mar 31 20:02:29 GMT 2025
|
PRIMARY | |||
|
DTXSID7059775
Created by
admin on Mon Mar 31 20:02:29 GMT 2025 , Edited by admin on Mon Mar 31 20:02:29 GMT 2025
|
PRIMARY | |||
|
137774
Created by
admin on Mon Mar 31 20:02:29 GMT 2025 , Edited by admin on Mon Mar 31 20:02:29 GMT 2025
|
PRIMARY | |||
|
9254
Created by
admin on Mon Mar 31 20:02:29 GMT 2025 , Edited by admin on Mon Mar 31 20:02:29 GMT 2025
|
PRIMARY |